key: cord-0994405-b7nzsqwd
authors: Schütz, Desiree; Ruiz-Blanco, Yasser B.; Münch, Jan; Kirchhoff, Frank; Sanchez-Garcia, Elsa; Müller, Janis A.
title: Peptide and peptide-based inhibitors of SARS-CoV-2 entry
date: 2020-11-13
journal: Adv Drug Deliv Rev
DOI: 10.1016/j.addr.2020.11.007
sha: edfc1e7ff76d88a0065d9071bfdfe387bb6fcc10
doc_id: 994405
cord_uid: b7nzsqwd

To date, no effective vaccines or therapies are available against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pandemic agent of coronavirus disease 2019 (COVID-19). Due to their safety, efficacy and specificity, peptide inhibitors hold great promise for the treatment of newly emerging viral pathogens. Based on the known structures of viral proteins and their cellular targets, antiviral peptides can be rationally designed and optimized. The resulting peptides may be highly specific for their respective targets and particular viral pathogens or exert broad antiviral activity. Here, we summarize the current status of peptides inhibiting SARS-CoV-2 entry and outline the strategies used to design peptides targeting the ACE2 receptor or the viral Spike protein and its activating proteases furin, transmembrane serine protease 2 (TMPRSS2), or cathepsin L. In addition, we present approaches used against related viruses such as SARS-CoV-1 that might be implemented for inhibition of SARS-CoV-2 infection.

Human pathogenic viruses pose an enormous threat to human health, society and economy. Unlike other pathogens, against most viruses neither specific pharmaceuticals nor vaccines are available. This situation is further complicated by the fact that viruses, such as human immunodeficiency virus type 1 (HIV-1), may develop resistance and that viruses keep (re-)emerging (e.g. Ebola and Zika virus) [1, 2] .

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the coronavirus disease 2019 (COVID- 19) , rapidly spread around the world causing many fatalities and devastating consequences for the health sector, the economy and the society in general. Although enormous efforts are made towards the rapid development of a vaccine, no vaccine has been approved so far. In addition, there is no assurance that vaccines against this coronavirus will provide long-lasting effective protection [3, 4] , and a vaccine will most likely not help those who are already infected.

Therefore, the development of therapeutic agents against this pandemic viral pathogen is urgently needed. To date, only convalescent plasma and remdesivir received emergency use authorization for clinical applications because they were reported to shorten the recovery period [5, 6] . Repurposing of some small molecule inhibitors such as favipiravir is currently investigated in clinical trials [7, 8] .

However, no effective therapy against SARS-CoV-2 is available to date.

Peptide and peptide-based inhibitors represent an attractive alternative to small molecules because peptides may be more efficient and specific than small molecule drugs and thus be better tolerated [9, 10] . Furthermore, peptide synthesis can be quickly implemented and tuned. In contrast, small molecules often require the development of new time-consuming and costly synthetic strategies. On the other hand, large-scale peptide synthesis may be expensive, depending on the composition of the trimers on the viral membrane. Each of the protomers can adopt an -open/up‖ or -closed/down‖ conformation ( Figure 2C ) [28] . The -open‖ conformation exposes the receptor binding domain (RBD) in S1, which includes the receptor binding motif (RBM) that directly interacts with ACE2. Both states, -open‖ and -closed‖, spontaneously and independently rearrange in each protomer, thereby determining the affinity to ACE2. Interestingly, the currently predominating SARS-CoV-2 variant carries a D614G mutation in S1 that favors the -open‖ conformation, thus rendering the RBD more accessible ( Figure 2B , C). In addition, glycosylation sites N165 and N234 favour the -open‖ state [29] . Accordingly, the SARS-CoV-2 D614G variant is more infectious in cell culture [30] . The S proteins of SARS-CoV-1 and SARS-CoV-2 share 76% sequence homology while the RBDs of SARS-CoV-1 and SARS-CoV-2 share 75% sequence homology [31] .. Both viruses utilize ACE2 as receptor to infect their target cells [23, 32, 33] . It has been reported that the ACE2-binding affinity of the RBD in the S1 subunit of SARS-CoV-2 is 10-to 20-fold higher than that of SARS-CoV-1 [34] .

This may explain the higher transmissibility of SARS-CoV-2 compared to SARS-CoV-1 [23] .

ACE2 binding to S1 induces drastic conformational changes that trigger the S2 subunit to mediate fusion. S2 is a typical viral class I fusion protein [35] , which includes a hydrophobic fusion peptide (FP), two α-helical hydrophobic (heptad) repeats (HR1 and HR2), a long linking loop region, and a transmembrane domain. HR2 is located close to the transmembrane anchor, and HR1 is close to the FP (Figures 1 and 2A ). After binding of the S1 domain to ACE2, the FP is inserted into the cellular membrane. The HR pair builds an α-helical anti-parallel complex between HR1 and HR2, where the loop acts as a hinge and brings the viral and cellular membranes in close proximity [36] . Finally, the three HR pairs of the S trimer form a six-helix bundle (6HB) motif where the HR1 helices form a central coiled-coil fusion core surrounded by three HR2 helices in an anti-parallel arrangement ( Figure 1 ). This conformation is highly stable and thought to help overcome the large energy barrier involved in membrane fusion [37] . The formation of 6HB in class I fusion proteins is a common process in viral entry and also used e.g. by HIV-1, herpes simplex virus and Ebola virus, among others [10, [38] [39] [40] [41] [42] [43] [44] [45] . Notably, the HR2 domains of SARS-CoV-2 and SARS-CoV-1 are identical, while J o u r n a l P r e -p r o o f Journal Pre-proof the HR1 domains show variations [46] . This might affect the interaction between HR1 and HR2 and consequently explain the superior plasma membrane fusion capacity of SARS-CoV-2 [47] .

For insertion into the cellular membrane, the FP must be accessible, which is achieved through cleavage at the S2' site by the transmembrane serine protease 2 (TMPRSS2). Alternatively, the pHdependent enzyme cathepsin L has been proposed to fulfil the processing function after endocytic uptake [3] . Notably, endocytic uptake and activating cleavage by cathepsin L may also overcome the requirement for furin-mediated priming of the S protein [48] . All these steps, S1/S2 and S2' cleavage, attachment to the cellular receptors, conformational changes of S1 and S2, FP insertion, rearrangement, and 6HB formation, are crucial for SARS-CoV-2 infection and might be targeted by peptide inhibitors. where missing resides were re-constructed by the SwissModel team [51] . The S1 subunit is shown in ochre with the receptor binding domain (RBD: 319-541) highlighted in violet and the specific receptor binding motif (RBM: 437-508) in light purple. The S2 subunit is shown in grey, with the fusion peptide (FP) region highlighted in pink and the heptad repeat 1 (HR1) region in yellow. S2' is shown in green and the S1/S2 cleavage site is indicated in purple. C) Ectodomain of the trimeric S protein. All RBDs of S1 subunits in their closed states are shown in red (PDB ID: 6VXX) and one RBD in its open state (PDB ID: 6VYB) is shown in blue. The site associated with the mutation D614G, which favors the open RBD conformation is indicated as green surface.

The first step of SARS-CoV-2 entry depends on binding of the viral S protein to its cellular receptor ACE2 [26] ( Figure 1C ). Several strategies to prevent the virus from entering the cell are based on interfering with RBD binding to the ACE2 receptor and range from designing peptides derived from the interacting site of the receptors, de-novo synthesis of RBD-binding peptides or alternatively, generation of peptides binding the S protein outside the RBD (Table 1 ) [52, 53] .

Binding to the ACE2 receptor is a characteristic shared by SARS-CoV-2, SARS-CoV-1, and HCoV-NL63 [26, 54] Accordingly, strategies to interfere with this interaction have been previously examined for SARS-CoV-1. Alanine scanning revealed that several charged amino acids between residues 22 and 57 of ACE2 are important for its interaction with the SARS-CoV-1 S protein [55] . On that basis, Han and coworkers synthesized six peptides from this region, expected to bind the SARS-CoV-1 S1 RBD and thus to block SARS-CoV-1 pseudoparticle binding. Two of these peptides (P4 and P5, Table 1 ) have half maximal inhibitory concentration (IC 50 ) values in the micromolar range.

Another peptide described in this study (P6), synthesized by linking two fragments with glycine, show higher potency with an IC 50 value of 0.1 μM [55] , verifying that the RBD is a suitable target for virus inhibition.

Peptides targeting domains in the S protein other than the RBD may also interfere with viral entry (Table 1 ). In one approach, domains involved in the adaptation to humans were identified by analyzing sequence variations in the SARS-CoV-1 S protein compared to related coronaviruses found in potential intermediate hosts, such as civets, cats, racoons and dogs. On this basis, ten peptides spanning these variation hotspots (some including the RBD), were synthesized and analyzed for their anti-SARS-CoV-1 activity [56] . Four of these peptides, which share a helical structure and are located at the monomers' contact surface of S1 and S2, were identified as antiviral (Table 1) . P2, derived from the N-terminal region of the S1 subunit close to the RBD, may hinder the conformational changes involved in ACE2 binding. P6 and P8, two other peptides identified in this study that target J o u r n a l P r e -p r o o f a domain of unknown function in the S1 and S2 subunit show IC 90 values of 113 µg/ml and 25 µg/ml, respectively, and might bind to exposed monomer interfaces to interfere with receptor-binding, proteinase-cleaving or virion-cell membrane-binding-sites [56] . The high similarity between the S proteins of SARS-CoV-1 and SARS-CoV-2 suggests that these peptides may also inhibit SARS-CoV-2, but this remains to be verified.

To address the inhibition of SARS-CoV-2, Cao and coworkers designed peptides, also known as miniproteins, using i) ACE2 as scaffold, and ii) de-novo sequencing based on RBD-binding interaction motifs. Following the first approach, they generated two promising agents, AHB1 and AHB2 ( Figure 3A , Table 1 ), which neutralized SARS-CoV-2 with IC 50 values of 35 and 16 nM, respectively [53] . Using the de-novo approach, two candidates, LCB1 and LCB3 ( Figure 3B , Furthermore, characterization by cryo-electron microscopy of LCB1 and LCB3 in complex with the SARS-CoV-2 S protein trimer reveal the underlying molecular interactions, as shown in Figure 3B .

This technique is a promising step towards identifying highly potent inhibitors of viral RBDs that might also help to combat future pandemics [53] .

Zhang and colleagues show in a preprint that the ACE2 α1-helix is important for the SARS-CoV-2 S1/RBD interaction (indicated in green in Figure 3A ) [52] and designed a 23-mer peptide derived from the α1-helix (SBP1) of the cellular receptor ( Figure 3A , Table 1 ). Bio-layer interferometry measurements indicate that this peptide specifically associates with the SARS-CoV-2-RBD with low nanomolar affinity. Unfortunately, its antiviral activity was not yet analyzed [52] .

The S protein S1 subunit receptor binding domain (RBD, violet) interacts with ACE2 (gold) via the receptor binding motif (RBM, light purple) (PDB ID: 6M0J). The interface residues of ACE2 interacting with the RBD are highlighted in green. This region was the scaffold for the designed peptides SBP1, AHB1, AHB2, LCB1 and LCB3 targeting the RBD [53] . B) SARS-CoV-2 S protein bound to the high-affinity LCB3 (in yellow) at the RBM (in light purple). The S1 subunit, outside the RBD, is shown as ochre surface and the S2 subunit is indicated in grey.

ACE2 is a membrane-associated aminopeptidase ubiquitously expressed in the heart, blood vessels, lung, kidney, gut, testis and brain [57] . ACE2 is part of the renin-angiotensinogen system where it antagonizes the angiotensin-converting enzyme (ACE) function and supports vasodilation. The coronaviruses SARS-CoV-1, CoV-NL63 and SARS-CoV-2 utilize ACE2 as entry receptor [58] .

Blocking viral entry receptors is a highly promising strategy to prevent virus infection. For example, the small molecule maraviroc that targets the HIV-1 co-receptor CCR5 is approved for clinical use [59] , providing proof-of-concept evidence that cellular entry receptors can be targeted for therapy.

Another small molecule, AMD3100, interferes with the second major HIV-1 co-receptor CXCR4 [60] . Examples for other receptor-specific peptides are the 16-mer peptide EPI-X4, which binds to CXCR4 and prevents CXCR4-tropic HIV-1 infection [19] or the hepatitis B and D virus inhibitor myrcludex B that binds to the sodium taurocholate co-transporting polypeptide (NTCP) [20, 21, 61] .

Several peptides that target ACE2 and inhibit SARS-CoV-1 infection have been described ( Table 1) .

Studies of SARS-CoV-1 show that peptides derived from the region comprising amino acids 270-837 of its RBD [62] [63] [64] can inhibit viral infection. Crystal structure analysis reveal that the 424-494 region is involved in interactions with ACE2 [65] . The R441A mutation abrogated cell entry by SARS-CoV-1 pseudoparticles [66] , suggesting that peptides targeting the region where this residue is found might display inhibitory activity. Accordingly, a peptide library based on residues 318-509 was synthesized and a plasmon resonance screening study yielded RBD-11b (438-443) as best ACE2binding peptide. However, RBD-11b inhibited infection by SARS-CoV-1 only at millimolar concentrations. The peptide was also active against CoV-NL63, suggesting conserved activity against viruses using ACE2 as receptor [67] . However, RBD-11b has not been tested against SARS-CoV-2.

In another approach, Ho and coworkers designed a set of peptides derived from the S protein of SARS-CoV-1 based on predicted hydrophilicity, surface probability, and chain flexibility. Three peptides, SP-4 (192) (193) (194) (195) (196) (197) (198) (199) (200) (201) (202) (203) , SP-8(483-494), and SP-10(668-679) ( Table 1 ) abrogated the interaction between a recombinant S protein and ACE2 and the latter inhibited SARS-CoV-1 pseudoparticle entry in Vero cells in the nanomolar range [68] . Another peptide S 471-503 derived from the RBD region (Table 1 ) was identified upon screening of a 10mer peptide library of SARS-CoV-1 B-cell epitopes.

S 471-503 also bound to ACE2 and reduced plaque formation of SARS-CoV-1 with an IC 50 value of 42 µM [69] . An RBD-independent approach was applied by Fukushi and coworkers. DX600, a peptide identified in a screening for ACE2 inhibitors [70] (Table 1) , inhibited VSV-SARS-CoV-1 pseudoparticles only modestly and not in a dose-dependent manner. This result suggests that the enzymatic activity of ACE2 is not important for infection, but that DX600 partially blocks ACE2 as SARS-CoV-1 receptor [71] .

Currently, several groups are working on ACE2-targeting peptides to inhibit SARS-CoV-2 (Table 1) .

the role of defensins, a well-known family of antimicrobial peptides [18] . Human defensin 5 (HD5) is the most abundant α-defensin in the intestine. Due to its lectin-like activity, HD5 binds lipids and glycosylated proteins [72, 73] , which makes ACE2 and the SARS-CoV-2 S protein its potential targets J o u r n a l P r e -p r o o f ( Figure 4 ). The binding of HD5 to ACE2 was confirmed using biolayer interferometry measurements.

Using confocal microscopy, it was shown that pretreatment with HD5 reduced SARS-CoV-2 pseudoparticle infection [18] , but antiviral activity against genuine SARS-CoV-2 isolates remains to be demonstrated.

Interestingly, passive interference with ACE2 was achieved by targeting integrin α 5 β 1 [74] . Integrins are receptors of extracellular matrix proteins, like fibronectin. Integrins have several interaction partners and play roles in cell-to-cell adhesion, cell migration, and as entry cofactors for viruses, such as human herpesvirus or HIV-1 [75, 76] . They have been shown to bind to a KGD sequence in ACE2 the RGD motif in the SARS-CoV-2 S protein [60, 156] . Therefore, Beddingfield and colleagues analyzed the potential antiviral activity of the fibronectin-derived anticancer peptide ATN-161 [74, 77] ( Figure 4 , Table 1 ), which might bind directly to the integrin, as well as to the RGD motif of the S protein, and to the KGD motif in ACE2 [60, 156] . They show that ATN-161 reduces SARS-CoV-2 infection (IC 50 ~ 3 µM), suggesting that this integrin may play a role during SARS-CoV-2 entry. In the clinical context, inhibitors of integrins are successfully used for the treatment of various diseases and clinical trials are underway to find more potent and safe integrin inhibitors. [157, 158] .

The next report discussed in this section is available as a preprint (Table 1 ). Watson and coworkers designed peptides, SARS-BLOCK™, that mimic the SARS-CoV-2 RBD domain ( Figure 4 ) and characterized their binding to ACE2 and to neutralizing antibodies by biolayer interferometry.

Peptides 1, 4, 5 and 6 inhibited RBD binding to ACE2 and show activity against SARS-CoV-2 pseudoparticles, with peptide 5 showing up to ∼95 % infection inhibition at the low micromolar range [78] . Yet, the antiviral activity of these peptides against genuine SARS-CoV-2 remains to be demonstrated.

Altogether, these studies show that the ACE2 receptor can be targeted to prevent virus attachment and infection. However, targeting host factors such as ACE2, might induce adverse effects as observed for other receptor targeting drugs. For example, life-threatening side effects have been reported for maraviroc [59] and AMD3100 was discontinued as HIV-1 treatment due to its severe side effects [79] . The SARS-CoV-2 receptor ACE2 is an important factor in the renin-angiotensin system, where J o u r n a l P r e -p r o o f interference might have deleterious consequences. Indeed, the development of the ACE2 inhibitor MLN-4760 was stopped due to toxicity concerns after phase Ib/IIa clinical trials [80, 81] . [78] that target ACE2 (gold). Similarly, human defensin 5 (HD5) is capable to block the interaction between ACE2 and RBD by targeting the binding interface of ACE2 [18] . The SARS-CoV-2 RBD contains an integrin-binding RGD motif (in red) and interacts with integrin α5β1. ACE2 interacts with α5β1 via a KGD binding site (green). This interaction might enhance SARS-CoV-2 binding to ACE2 [74] (left panel). The peptide ATN-161 binds tightly to the S protein and to α5β1, resulting in the disruption of α5β1 binding to ACE2 and to RBD, thus reducing SARS-CoV-2 infection (right panel).

Activation of the SARS-CoV-2 S protein requires proteolytic cleavage at two sites. First, the S protein is cleaved and primed at the poly-basic S1/S2 site by the host protease furin, which generates two distinct subunits that remain non-covalently linked (Figures 2 and 5 ). The second cleavage site is found in the S2 region (S2′) and is processed by the plasma membrane-associated protease TMPRSS2, which releases the FP of S2 [35] . Alternatively, lysosomal cathepsin L can process and activate the S protein independently of furin-mediated J o u r n a l P r e -p r o o f priming, after endosomal uptake. However, its role in vivo is not entirely clear [82] [83] [84] .

Inhibition of these proteases blocks SARS-CoV-2 infection, as described for small molecule inhibitors of TMPRSS2, such as camostat mesylate [26] , or, for cathepsin L, e64d [85] .

Therefore, identifying and designing peptides that disturb this process is another strategy to develop therapeutic agents against SARS-CoV-2 (Table II) . Inhibitory peptides can be designed by mimicking known cleavage motifs.

When designing protease inhibitors to prevent viral infection, it has to be considered that viral glycoproteins can frequently be primed and/or activated by several redundant proteases recognizing similar target sequences. For example, hemagglutinin of influenza viruses can not only be cleaved by TMPRSS2, but also by TMPRSS4, human airway trypsin-like protease (HAT) or even bacterial proteases [86] [87] [88] . Similarly, TMPRSS4 was recently shown to facilitate SARS-CoV-2 spike fusogenic activity thus promoting virus entry into host cells [89] , and furin-like proprotein convertases may process its poly-basic S1/S2 site [27] . In addition, other unknown proteases might activate the S protein. Thus, combined targeting of several proteases might be required for efficient inhibition [84] .

Journal Pre-proof [84] . The inhibitors MI-1852 and dec-RVKR-cmk target furin and related protein convertases, while Aprotinin is a broad-range protease inhibitor [84, 90] . Teicoplanin targets cathepsin L cysteine proteinase [91] . The structure of TMPRSS2 was obtained from the SwissModel repository with ID code O15393 [92] . This model was built by the SwissModel team based on the structure with PDB ID 1Z8G [93] . The structure of furin corresponds to that reported with PDB ID 4Z2A [94] , and the representation of cathepsin L was built based from the structure reported with PDB ID 2YJ9 [95] . The structure of the S protein corresponds to a model with reconstructed loops based on the structure with PDB ID 6ZGE [50, 96] . The colour code used to represent the spike protein is: orange, S1 subunit of the S protein; grey, S2 subunit of the S protein; green, S2' cleavage site; purple, S1/S2 cleavage site. The same colour scheme is used to highlight the active sites of the corresponding enzymes.

As mentioned above, the SARS-CoV-2 S protein is cleaved by furin at a poly-basic cleavage site into its S1 and S2 subunits. This feature distinguishes SARS-CoV-2 from closely related bat coronaviruses and SARS-CoV-1, which harbor a mono-basic S1/S2 site that cannot be cleaved by furin. Notably, furin plays a major role in the proteolytic activation of a broad range of viruses, including several flavi-, filo-, paramyxo-and retroviruses [27, 97] . It is a proprotein convertase that is ubiquitously expressed in eukaryotic tissues and physiologically J o u r n a l P r e -p r o o f cleaves precursors of multiple proteins, including growth factors, hormones, cell surface receptors, and adhesion molecules during their transport along the secretory pathway. Furinmediated cleavage not only activates multiple viral glycoproteins, but also a variety of bacterial toxins and cellular oncoproteins. Thus, furin inhibition is already explored in clinical trials for the treatment of cancer [27] and a promising approach to treat infectious diseases.

The poly-basic consensus sequence targeted by furin and related proprotein convertases is R- [97, 98] . Previous studies have shown that the peptidomimetic furin inhibitor decanoyl-RVKR-chloromethylketone (dec-RVKR-cmk) inhibits the activation of different viral glycoproteins [99] [100] [101] . Most likely, this ketone-based peptide inhibits furin by a chemical reaction leading to the formation of a hemiketal and thus to an irreversible block of its enzymatic activity [102] . Importantly, dec-RVKR-cmk was shown to block SARS-CoV-2 S processing ( Figure 5 ) [103] and to inhibit syncytium formation and virus infection with an IC 50 of 5 µM (Table II) 190-fold at a dose of 10 µM [84] . Together, these studies suggest that furin inhibitors might have the potential to be clinically applied not only against cancer but also infectious diseases including SARS-CoV-2.

TMPRSS2 is a serine protease involved in many physiological and pathological processes and is widely expressed in epithelial cells of the respiratory, gastrointestinal, and urogenital tracts [104] . Moreover, TMPRSS2 is involved in the proteolytic activation of many respiratory viruses, including SARS-CoV-1, SARS-CoV-2 and MERS-CoV [26, 97] . Mice J o u r n a l P r e -p r o o f deficient in TMPRSS2 showed reduced pathology after infection with SARS-CoV-1 and MERS-CoV, indicating that inhibition of proteolytic activation may exert beneficial effects [105] . Treatment with the small molecule camostat mesylate confirmed that inhibition of TMPRSS2 suppresses SARS-CoV-2 infection [26] .

Bestle and coworkers demonstrated that a knockdown of TMPRSS2 prevents proteolytic activation and spreading of SARS-CoV-2 in human airway epithelial cells (Calu-3) cells [84] .

The polypeptide Aprotinin ( Figure 5 ) from bovine lung is a broad-range inhibitor of serine proteases that inhibits TMPRSS2 and thus decreases replication of influenza [106] and

Sendai virus [107] . The safety and efficacy of Aprotinin was shown in clinical trials, where inhalation reduced symptoms of patients suffering from influenza [106] . When adding

Aprotinin to SARS-CoV-2 in vitro, it suppressed infectious virus production by 25-to 100fold at a concentration of 10 µM at 16-48 h post infection. However, after 72 h post-infection the inhibitory effect was abolished [84] . Additionally, the team tested the peptidomimetic inhibitor MI-432 and its analog MI-1900 ( Figure 5 , Table 2 ) that have been designed to target serine proteases and shown to inhibit TMPRSS2 and the replication of influenza virus [108] .

Peptidomimetics are pseudopeptide sequences that have been tuned to enhance bioavailability, improve transport through the blood-brain barrier, and to exhibit reduced rates of clearance [12] . Both peptidomimetic inhibitors, MI-432 and MI-1900 reduced viral titers more potently than Aprotinin [84] . Finally, combinations of TMPRSS2 and furin inhibitors were analyzed. Combining the furin inhibitor MI-1851 ( Figure 5 ) with either Aprotinin, MI-432 or MI-1900 generally increased antiviral efficacy. MI-1851 together with MI-432 are most effective and reduce virus titers to up to 32-fold lower levels compared to each inhibitor alone [84] . Thus, TMPRSS2 and furin inhibitors targeting different steps of S protein processing and activation hold promise for therapeutic development (Table 2 ).

In a preprint report, Wettstein and coworkers recently showed that α1-antitrypsin, an endogenous serine protease inhibitor, hinders SARS-CoV-2 infection [109] . It was previously shown that α1-antitrypsin inhibits proteolytic activity of TMPRSS2 [110] . Thus, α1antitrypsin may block SARS-CoV-2 infection by inhibiting TMPRSS2-mediated S protein activation. Notably, plasma purified α1-antitrypsin has been approved as augmentation therapy for α1-antitrypsin deficiency, a hereditary disorder characterized by low plasma concentrations of the serine protease inhibitor. This allows drug repurposing and several clinical studies that aim to evaluate the therapeutic efficacy of α1-antitrypsin in hospitalized COVID-19 patients have been initiated [111] .

Cysteine cathepsins are a group of ubiquitously expressed proteases that are localized in endosomes and lysosomes where they activate the SARS-CoV-1 and -2 S proteins [112] at a pH range of 3.0-6.5 [85, 113] . S protein activation by cathepsin L is most likely to occur in the absence of TMPRSS2 and/or furin after endocytosis. However, the sites of cleavage and whether cathepsin L fulfils an important function in vivo is unclear. In fact, it has been suggested that activation by cathepsins is a mechanism acquired through cell culture and dispensable for SARS-CoV-2 infection in vivo [82] [83] [84] . Consistent with this, inhibition of cathepsin L by the small molecule e64d reduce SARS-CoV-2 pseudoparticle infection in TMPRSS2 negative HEK293T and Vero cells [26, 84] . However, upon TMPRSS2 expression, the effect of e64d is abolished, but by combining e64d with camostat mesylate show synergistic effects [26] . Many FDA-approved cathepsin L inhibitors exist, supporting their clinical safety and suggesting its supportive activity as combination therapy [114] .

One agent that interferes with cathepsin L activity is peptide P9 (Table 2) , which is derived from mouse β-defensin-4 and shown to exert broad antiviral activity against SARS-CoV-1, MERS-CoV, and influenza virus. P9 directly binds to SARS-CoV-2 particles and inhibits endosome acidification (Figure 1 ) thereby indirectly interfering with the activity of cathepsin L [115] . P9 was optimized by increasing the number of proton-accepting amino acids to generate P9R [116] ( Table 2 ). This peptide shows antiviral activity against the coronaviruses MERS-CoV, SARS-CoV-1, and SARS-CoV-2 with IC 50 values in the low µg/ml range. P9R

was also active against the pH-dependent influenza viruses A(H1N1)pdm09 and A(H7N9), as well as a non-enveloped rhinovirus [116] . Of note, the anti-SARS-CoV-2 effects of P9R were found on TMPRSS2 negative Vero E6 cells, while its activity in TMPRSS2 positive cells is unknown. Altogether, these results show that targeting acidification broadly prevents infection by viruses that depend on endosomal acidification. This effect may be related to the viral glycoprotein that depends on acidification for rearrangement (in case of influenza) or the endosomal cathepsin L that activates the viral glycoprotein (in case of SARS-CoV-1 and SARS-CoV-2). Although targeting acidification might have several side effects in a physiological setting, A(H1N1)pdm09 infected mice showed better outcomes upon intranasal treatment with P9R [116] . A follow up study, currently available as preprint, suggests that virus-binding P9R-derived oligomers may cross-link viral particles [117] . The analyzed eight-branched 8P9R is more potent than P9R in blocking SARS-CoV-2 entry and also inhibits infection of TMPRSS2 positive Calu-3 cells by aggregating viral particles, confirming its dual-antiviral mechanism. The antiviral effect was confirmed in vivo in mice and hamsters where its application decreased viral loads. In contrast, the TMPRSS2 inhibitor camostat mesylate was inactive, further illustrating that blocking only one entry pathway might be insufficient [117] .

The glycopeptide antibiotic teicoplanin (Table 2) , commonly used to treat gram-positive bacterial infections [118] , has also been shown to inhibit cathepsin L ( Figure 5 ), SARS-CoV-1 and MERS-CoV [119] . A study currently available as preprint shows that the SARS-CoV-1

and SARS-CoV-2 cathepsin L cleavage sites are conserved and that teicoplanin also prevents infection of SARS-CoV-2 pseudoparticles with an IC 50 of 1.66 µM [91] . Additionally, teicoplanin seems to inhibit the viral 3-chymotrypsin-like protease (3CL pro ) of SARS-CoV-2 that is important for viral spread [120] . In the clinics, teicoplanin has been applied to treat

Staphylococcus aureus superinfections that may occur as major complication in COVID-19

patients [121] that simultaneously might act antiviral. However, an effect on SARS-CoV-2 remains to be shown [122] .

The fact that cathepsin L inhibition does not interfere with infection of TMPRSS2 expressing lung derived Calu-3 cells [84] , suggests that it is not a suitable target for monotherapy.

However, combinations of furin, TMPRSS2 and cathepsin inhibitors showed higher activities than the individual agents. Thus, a combination therapy targeting viral fusion at the cell surface as well as in endosomes might be useful against SARS-CoV-2 [26, 84] . As with other approaches, unwanted side effects arising from broad interference with the activity of physiologically relevant proteases need to be considered [123] .

Another promising antiviral target is the fusion mechanism of viral class I fusion proteins.

Research on HIV-1 showed that mutations in the HR regions often result in a fusion-deficient phenotype [124, 125] , which revealed HR rearrangement as a potential target. In the 1990s, peptides derived from the HR1 and HR2 of the HIV-1 glycoprotein 41 (gp41) were designed.

These peptides inhibit HIV-1 entry [126] [127] [128] , revealing crucial information on the viral fusion mechanism [129] . The peptides designed to mimic one of the HR regions were found J o u r n a l P r e -p r o o f to interact with the complementary HR region and to inhibit conformational rearrangements, 6HB formation, and thus membrane fusion ( Figure 6A, B) . These so called C peptides were further developed into HIV-1 entry inhibitors [130, 131] . The best known C peptide is T20 [11] , which found application in clinics, thus highlighting the potential of peptidic fusion inhibitors [10] . Peptides derived from the HR regions of other class I fusion protein viruses [36, 38, [40] [41] [42] , such as parainfluenza [43] , Ebola [39] , Newcastle disease [45] , and respiratory syncytial virus [44] , inhibit viral entry with nanomolar to micromolar activities.

The strategy of designing and synthesizing peptides that overlap with HR regions was also applied to members of the Coronaviridae family e.g. HCoV-229E [132] , SARS-CoV-1 [133, 134] , and MERS-CoV [135] [136] [137] (Table 3 ). Liu and coworkers identified a HR2derived peptide from SARS-CoV-1, namely CP-1, that binds to HR1 and blocks 6HB

formation and fusion of SARS-CoV-1 [134] . Other SARS-CoV-1 HR1-targeting peptides have been developed in the 2000s by several research groups, and show activities in the nanomolar to low micromolar range [133, 134, [138] [139] [140] . In comparison, peptides derived from HR1 (and thus targeting HR2) are often poorly active [133, 134, 139] , possibly due to their propensity to self-aggregation [129] .

Usually, HR-derived peptides are specific for their corresponding viruses. In 2019, however, a HR peptide was identified that shows pan-corona virus inhibiting activity. While HR2P peptides from MERS-CoV and SARS-CoV-1 lack broad-spectrum antiviral activity against heterologous human coronaviruses, the peptide OC43-HR2P exhibit broad-spectrum activity against both α-HCoVs and β-HCoVs [141] (Table 3) . By specific changes in the amino acid sequence, the antiviral activity and solubility of this peptide was further optimized resulting in the EK1 derivative ( Figure 6B , C). EK1 targets HR1 domains of several human coronaviruses, including SARS-CoV-1 and MERS-CoV [47, 141] . Importantly, EK1 display potent prophylactic and therapeutic in vivo activity against MERS-CoV and HCoV-OC43 J o u r n a l P r e -p r o o f infections by intranasal application in mice [141] . Furthermore, EK1 proved to be safe and shows only low immunogenicity in vivo [141] . Thus, it represents the first broadly active HRtargeting inhibitor with potential applications against various coronaviruses.

EK1 was also active against SARS-CoV-2 with an IC 50 value of 2.5 µM in TMPRSS2

negative Vero E6 cells [47] . Interestingly, the IC 50 value was about 10-fold lower in TMPRSS2 positive Caco-2 cells, suggesting that fusion at the cell surface is more potently inhibited by this peptide [142] . It is known that the conjugation of lipids to fusion inhibitory peptides can increase their activity and in vivo stability. This is likely due to an increased affinity of the peptide for membranes [143] , as shown for the peptide LP-19 against HIV-1 [144] . Accordingly, cholesterol was covalently attached to the C-terminus of EK1 linked by a PEG spacer to generate EK1C4 [47] ( Figure 6B ). In agreement with previous studies [133, 134, 139] , HR1-derived J o u r n a l P r e -p r o o f peptides show no inhibitory activity [46] . The peptide IPB-01 was modified by adding a cholesterol group to its C-terminus (IPB-02), which reduce IC 50 values against SARS-CoV-2 and SARS-CoV-1 pseudoparticles to 0.08 µM and 0.25 µM respectively [145] . Additionally, a structure-activity relationship study with truncations of IPB-02 allowed to identify sequences essential for the inhibitory effect [145] . In line with these results, Zheng et al [56] reported the design of ten peptides based on sequence variations of the S protein (Table 3) .

Of those, peptide P10 resembles the HR2 region and thus exhibits antiviral activity by targeting HR1. The other active peptides P2, P6, and P8 have been discussed in chapter 2.

A study available as preprint reported optimization of a peptide, varying only in a single amino acid from 2019-nCoV-HRP2 [46] , by PEGylation, lipidation and dimerization [146] .

highly active on TMPRSS2 positive cells with IC 50 values as low as 3.8 nM (Table 3) . Most notably, intranasal application in ferrets protected them from viral transmission when cohoused with SARS-CoV-2 infected ferrets [146] .

Altogether, these studies show that targeting the HR1 domain by peptides derived from the HR2 region is a promising strategy for generating fusion inhibitors against many class I fusion protein viruses, including SARS-CoV-2. The high HR homology in coronaviruses allowed to generate the broadly active and potent fusion inhibitor EK1C4 for potential treatment of infection by different coronaviruses including SARS-CoV-2 (Table 3 ).

Journal Pre-proof B) The HR1 domains form a three-helices bundle that serves as scaffold for the fusion core (left panel). The fusion core, shown in purple, is formed by binding of the three HR2 domains to the HR1 bundle. By binding of HR2-derived peptides (in blue) to the HR1 domains (right panel), the formation of the six-helix bundle is inhibited. The mechanism of activity of these peptides involves their tight binding to HR1, thus preventing the association of the HR2 domains. HR1-derived peptides include IPB02 [145] , EK1 [141] , EK1C4 [47] , 2019-nCoV-HRP2 [46] and [SARS-CoV-2 HRC -peg 4 ] 2 -chol [146] . C) The three HR1 domains in A) are also shown as surface projections (left panel) coloured by residue type (green: polar, red: acidic, blue: basic, white: non-polar). The molecular surface evidences open hydrophobic crevices in the regions between the helices. The EK1 peptide is presented with the molecular surface of the main interaction fragment coloured by residue type, the remaining residues are shown as a grey coil (middle panel). The surface of the interaction motif of EK1 depicts two welldefined faces with inversed polarity. Such distribution of residues allows the non-polar face to effectively couple to a non-polar crevice of the 6HB while the polar face shields the hydrophobic core, thus favouring the binding of this peptide (right panel). The side chains of charged residues at the polar face of EK1 are presented with sticks and the residues are labelled. The figure of the 3HR1-EK1 complex was generated using the coordinates reported with PDB ID 5ZVM [141] .

To find other targets relevant to the fusion process, the Wimley and White interfacial hydrophobicity scale [147] was used for the identification of membrane-interacting regions within S2 [148] . Membrane interactions, especially those involving the FP, could be important for viral fusion and thus represent potential antiviral targets [148] . Five peptides analogous to the identified regions were tested for inhibition of SARS-CoV-1 entry (Table 3) .

All peptides were active, but the most potent inhibition of SARS-CoV-1 plaque formation was found for WW-III and WW-IV with IC 50 values between 2-4 μM. Since both peptides are derived from the loop domain between HR1 and HR2, the authors speculate that they might sterically hinder extension of the FP or transition to the 6HB conformation [148] .

Similarly, the WW-V peptide, which corresponds to the aromatic region overlapping with the C-terminal HR2 domain, might interfere with rearrangement. In comparison, the WW-I and WW-II peptides correspond to the N-terminus of the S2 region containing the FP, suggesting that they might interfere with FP insertion in the cell membrane. Compounds targeting the FP of class I fusion proteins have previously shown to exert antiviral activity. For example, the α1-antitrypsin-derived fragment VIRIP targets the FP of HIV-l and prevents infection [11] .

An optimized derivative with increased plasma stability and anti-HIV-1 activity reduce viral loads in treatment naïve patients demonstrating that viral FPs ae druggable viral structures [11, 149, 150] . Currently, this strategy has not been explored for coronaviruses and peptides binding the FP of the SARS-CoV-2 S protein might represent an alternative to HR-and RBD-targeting peptides.

As it is the case of many disorders, infectious or not, in-silico strategies for the design and screening of active compounds, as well as for studying the dynamics of the involved proteins are key to global efforts aiming to identify novel therapeutics and vaccines [151] [152] [153] , also in the context of the SARS-CoV-2 pandemic [53, [154] [155] [156] [157] [158] [159] [160] [161] [162] . In this section, we provide an J o u r n a l P r e -p r o o f overview of computational approaches used for delivering timely predictions of peptide and peptide-based inhibitors targeting the virus's entry mechanism.

As discussed, the entry process of SARS-CoV-2 in human cells is mediated by interactions between S proteins at the surface of the viral membrane and the ACE2 receptor on human cells. Consequently, most computational protocols aimed at preventing the proteinprotein interaction between the ACE2 receptor and the RBD domain of the SARS-CoV-2 S proteins [53, [155] [156] [157] [158] [159] [160] [163] [164] [165] [166] . The structure of this complex was elucidated early in this year, 2020, and the first coordinates were reported in the Protein Data Bank under the ID codes: 6VW1 [167] , 6M17 [168] , 6lZG [169] , and 6M0J [33] . Specifically, peptide design strategies mainly focused on extracting candidates based on the ligand binding motif of the ACE2 receptor, and optimizing the sequences of these peptides to obtain potent inhibitors targeting the RBD [53, [155] [156] [157] [158] [159] [160] 163, 164, 166] . Similarly, efforts have been devoted to the in-silico design of peptide inhibitors targeting the ACE2 receptor [165] and the HR1 domain of the S protein [154] . The computational workflow used in these designs usually comprised well-established techniques such as homology modeling, computational mutagenesis, docking protocols, rescoring methods and molecular dynamics simulations ( Table 4 ). The applications of these techniques allowed the exploration of peptide libraries [158, [163] [164] [165] and to build models of new peptides [53, [154] [155] [156] [157] [158] [159] 166] , as well as the structural and dynamical characterization of the interactions of ACE2 and the peptides with the interface of the viral S protein [156, 160, 164, 166] . In addition, computational protocols have been used to predict the antiviral activity and the toxicity of peptides with potential inhibitory effect [154, 158] (Table   4) .

A key step for the design of inhibitors is to gain knowledge of the structural and dynamical

properties of the target and its protein partners. In this respect, a molecular dynamics study of the ACE2 receptor bound to the RBDs of both, SARS-CoV-1 and SARS-CoV-2, was J o u r n a l P r e -p r o o f reported [160] , revealing specific interactions stabilizing the binding mode of the viruses.

Recently, a full-length model of the S protein, including multiple glycosylated sites was presented [29] . Based on this model, obtained from extensive and rigorous simulations, two key glycosylation sites (N165 and N234) that modulate the ratio between the open and closed states of the S protein were characterized [29] . (Pantano, SIRAH force field [172] , AMBER20). In addition, ongoing efforts delivered the first coarse-grained model of the SARS-CoV-2 virion structure [49] . This model represents a step forward for the study of conformational events and interactions between SARS-CoV-2 proteins, using molecular dynamics simulations.

Although at relatively early stages, these studies evidence the potential of computational tools for the development of new inhibitory peptides against SARS-CoV-2 and future pandemics.

The application of these computational tools allowed the rapid screening of peptide candidates and provided structural and dynamical information of interaction patterns key for the rational design of compounds with therapeutic potential.

The high potency and selectivity as well as the pharmacological profile and ease of synthesis of peptides enables their translation into clinical applications [173] . Frequently, peptides are highly specific while being tolerable and safe. Importantly, their interactions and degradation pathways are often predictable. Thus, absorption, distribution, metabolism and excretion J o u r n a l P r e -p r o o f (ADME) properties can be anticipated and improved [173, 174] . In this respect, administration and targeted tissues play critical roles in ADME and determine therapeutic efficacy. Peptides are rarely orally available and to achieve systemic distribution, they are often delivered intravenously or subcutaneously [174] . Systemically available peptides face plasma protein binding, proteolytic degradation, metabolization in the liver or free filtration by the kidneys, which may drastically reduce plasma half-life and concentrations at the targeted tissue [174] . Thus, a limitation for the clinical application of peptide inhibitors is their lack of systemic bioavailability [9] .

However, the sites of SARS-CoV-2 infection and replication, i.e. the upper and lower airways, are highly accessible [175] , which renders the need for oral availability or systemic application obsolete. Respiratory diseases are commonly targeted by nasal or oral sprays or inhalation of small molecules allowing direct delivery to the target organ. Several peptidebased inhalants have already made it into the market. For example, lucinactant is applied as inhalable surfactant replacement to treat the respiratory distress syndrome (RDS) [174, [176] [177] [178] . Other pulmonary peptide therapeutics such as aviptadil against RDS and pulmonary hypertension, as well as inhalable peptides targeting cystic fibrosis, asthma, and infectious diseases, are currently in clinical trials [176] . Additionally, inhalation can be used to systemically deliver drugs as the lungs have a large surface area, are highly vascularized and the epithelial barrier function is low, which allowed e.g. the development of inhalable insulin [177] .

Inefficient passing of the respiratory epithelium after inhaled delivery may even be beneficial because it results in a high concentration directly in the lung instead of systemic distribution thereby increasing local potency and decreasing adverse effects. [179] . Application of peptides in the lung usually leads to long-lasting local activity because proteolytic activity is low [180, 181] and the number of antiproteases high [178] . Challenges of pulmonary delivery J o u r n a l P r e -p r o o f include the homogenous deposition of peptides throughout the alveoli whilst passing the barriers of the mucous layer and the elimination via mucociliary clearance [182] . Strategies to improve peptide formulation and aerosolization such as optimizing aerodynamic diameters, mucoadhesion, or peptide release are currently investigated [174] . Thus, the oral, nasal and pulmonary mode of delivery is easy and feasible, absorption and distribution occur directly at the targeted site, the metabolization is reduced, and the elimination occurs mainly via mucus flow which reduces potential side effects. Therefore, locally applied extracellular peptides that do not need to enter the blood stream to block SARS-CoV-2 infection might be strong candidates for clinical development.

Of the anti-SARS-CoV-2 peptides reported to date, the HR-analogue EK1C4 is the most promising candidate for clinical development. It directly targets the virus, does not interfere with cellular functions, has already been optimized for potency and stability and was tolerated and effective in vivo in a mouse model for SARS CoV-2 infection [47] .

Furthermore, the pan-coronavirus activity of EK1C4 suggests that might also be effective in future coronavirus outbreaks. Similarly, the optimized peptide based on 2019-nCoV-HRP2 [46] shows lower nanomolar IC 50 values in vitro and prevented SARS-CoV-2 transmission in vivo [146] . Alternatively, the miniproteins LCB1 and LCB3 that also target the S protein are interesting for further development, as they show activities in the picomolar range [53] .

However, with 56-160 amino acids, these miniproteins are still very large, which might result in high production costs and low output.

To advance translation of peptide inhibitors into clinical applications these peptides can be optimized for bioavailability, potency, stability, safety and size to allow large-scale manufacturing. Successful translation of a peptide inhibitor with nanomolar IC 50 values in vitro into the clinics has been shown for the HIV-1 HR analogue T20 (enfurvitide) [183] .

However, T20 suffered from low potency, short half-life, induction of local immune J o u r n a l P r e -p r o o f responses and quick development of resistance in vivo [10, 184] . Notably, next-generation T20-related peptide pose a higher barrier to resistance and show substantially higher potency and stability [185] . In addition, most of these drawbacks are specific for HIV-1, which causes life-long and systemic infections and is rapidly mutating. Thus, T20 treatment requires constant plasma levels and hence repeated injections over long time periods. In contrast, prevention and treatment of an acute and locally confined infection such SARS-CoV-2 might benefit from the temporal and topical application of a highly potent peptide solution. This short application time and broad activity of EK1C4 together with the relatively low mutation rates of SARS-CoV-2 might prevent viral escape. The prophylactic potential of the HR2peptide-based nasal spray has already been shown [146] and more studies in animal models to assess this approach seem highly warranted. The process of developing peptide drugs is usually shorter than for small molecules but might still take years [173, 186] . However, even anticipating that vaccination efforts will be successful, the development of therapeutics is essential as successful treatment of infected individuals to prevent severe COVID-19 remains a clinical challenge. Here, novel peptide-based agents may be a promising alternative to drug repurposing and small molecules. Early treatment of upper airway infections might be highly beneficial as it potentially prevents immunopathological processes and viral dissemination into the lower airways and other tissues and organs [187, 188] . Similarly, reducing viral spread in patients already suffering from COVID-19 might improve recovery. Thus, shortterm application of peptides could be useful as prophylactic or therapeutic intervention and help to gain control over this pandemic.

The prevention and treatment of the pandemic SARS-CoV-2 requires the rapid development of effective vaccines and antivirals to limit viral spread and associated fatalities. Fast design and synthesis, high target specificity and reduced side effects make peptides a great scaffold J o u r n a l P r e -p r o o f for new drugs [9, 10, 189] . Previous data on related viruses and the rapidly increasing knowledge of the SARS-CoV-2 entry process allowed the computational modeling, identification, characterization and optimization of antiviral peptides interfering with the proteolytic activation of the S protein, the binding to ACE2, or the membrane fusion process, Animal studies are needed to assess the potential of this approach as an alternative to repurposing strategies and small molecule drugs against SARS-CoV-2. Table 4 : Summary of the computational tools primarily used to design peptides targeting the Spike protein and to study the interactions between RBD and the ACE2 receptor.

Purpose Tools To build structural models of new peptide sequences, based on the scaffold of the known Spike-RBD structure, as well as for adding missing fragments in the elucidated structures [29, 53, 154, 155, 157] SwissModel [51] , MODELLER [191] and I-TASSER [192] , and Rosetta [193] with RIF docking [194] To reconstruct missing residues and preparing structures for the simulations. Optimizations of rotamers as well as performing minimization procedures and alanine scanning analyses [157, 159, 160] Schrödinger (Prime) [195] , UCSF Chimera software [196] , FoldX [197] and the proprietary software BIOVIA Discovery Studio [198] , CHARMM-GUI [199] For peptide protein docking [53, 154, 155, 157, 163, 164, 166] HADDOCK [200] , HPEPDOCK [201] , ClusPro [202] , Rosetta [193] , and ZDOCK [203] Evaluation of the antiviral potential of new peptides and toxicity likelihoods for such peptides [154, 158] AVPpred [204] and AVP-IC50pred [205] as well as as well as ToxinPred [206] Re-scoring of the peptide candidates´ affinity to the Spike protein [157] PRODIGY [207] Peptideprotein interaction energies and free energy changes [154, 156] NAMD [208] MMGBSA [209] with the VSGB 2.0 solvation model, as implemented in the Schrödinger Prime suite of programs [195] To sample the conformational variability of the S protein and the peptide candidates derived from truncated structures of the Spike -ACE2 interface [29, 156, 160, 166] NAMD [208] , DESMOND [171] and GROMACS [210] Analyses and visualization of the molecular dynamics simulations [29, 160] VMD [211] and and MDtraj [212] We thank Elisabeth Braun and Daniel Sauter for critically reviewing the manuscript. This We declare no conflicts of interest.

Drug resistance in HIV-1

Emerging/re-emerging viral diseases & new viruses on the Indian horizon

Cell entry mechanisms of SARS-CoV-2

Why are vaccines against many human viral diseases historic perspective?

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Favipiravir: A new and emerging antiviral option in COVID-19

Favipiravir in Hospitalized COVID-19 Patients (FIC)

Basics and recent advances in peptide and protein drug delivery

A rationally engineered anti-HIV peptide fusion inhibitor with greatly J o u r n a l P r e -p r o o f reduced immunogenicity

HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry

Peptidomimetics, a synthetic tool of drug discovery

Immunosilencing peptides by stereochemical inversion and sequence reversal: retro-Dpeptides

Inhibitory activity and molecular mechanism of protegrin-1 against porcine reproductive and respiratory syndrome virus in vitro

Antiviral Activity of the Human Cathelicidin, LL-37, and Derived Peptides on Seasonal and Pandemic Influenza A Viruses

Antiviral peptides as promising therapeutic drugs

Antiviral mechanisms of human defensins

Inhibits SARS-CoV-2 Invasion by Cloaking ACE2

EPI-X4, a novel endogenous antagonist of CXCR4

Fine Mapping of Pre-S Sequence Requirements for Hepatitis B Virus Large Envelope Protein-Mediated Receptor Interaction

First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B

of the I.C. on T. of Viruses, The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

A pneumonia outbreak new coronavirus of probable bat origin

Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses

The spike protein of SARS-CoV -a target for vaccine and therapeutic development

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Furin-mediated protein processing in infectious diseases and cancer

Conformational transition of SARS-CoV-2 spike glycoprotein between its closed and open states

Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein

Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant

Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop

Return of the Coronavirus: 2019-nCoV

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science (80-. )

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the J o u r n a l P r e -p r o o f fusion core complex

Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme

A Heptad Repeat in Herpes Simplex Virus 1 gH, Located Downstream of the α-Helix with Attributes of a Fusion Peptide, Is Critical for Virus Entry and Fusion

Functional importance of the coiled-coil of the Ebola virus glycoprotein

Heptad repeat 2-based peptides inhibit avian sarcoma and leukosis virus subgroup a infection and identify a fusion intermediate

A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus-cell fusion: an emerging similarity with functional domains of other viruses

Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein

Peptides corresponding to the heptad repeat sequence of human parainfluenza virus fusion protein are potent inhibitors of virus infection

Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion

Six-helix bundle assembly and characterization of heptad repeat regions from the F protein of Newcastle disease virus

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein

A Multiscale Coarse-grained Model of the SARS-CoV-2 Virion

SWISS-MODEL: homology modelling of protein structures and complexes

The first-in-class peptide binder to the SARS-CoV-2 spike protein

De novo design of picomolar SARS-CoV-2 miniprotein inhibitors

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry

Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor

Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

The pivotal link between ACE2 deficiency and SARS-CoV-2 infection

Two-year safety and virologic efficacy of maraviroc in treatmentexperienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2

New developments in anti-HIV chemotherapy

Hepatitis B and D Viruses Exploit Sodium Taurocholate Co-transporting Polypeptide for Species-Specific Entry into Hepatocytes

Amino acids 270 to with receptor

The SARS-CoV S glycoprotein: expression and functional characterization

A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2

Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2

Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain

A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2

Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction

Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library

Novel peptide inhibitors of angiotensin-converting enzyme 2

Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein

Paneth cell antimicrobial peptides: topographical distribution and quantification in human gastrointestinal tissues

Design of a Potent Antibiotic Peptide Based on the Active Region of Human Defensin 5

The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS

Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α4β7

Beyond RGD: virus interactions with integrins

ATN-161 reduces virus proliferation in PHEV-infected mice by inhibiting the integrin α5β1-FAK signaling pathway

Peptide Antidotes to SARS-CoV-2 (COVID-19)

Effectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practice

Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment

Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis

Wild-type human coronaviruses prefer cellsurface TMPRSS2 to endosomal cathepsins for cell entry

Clinical Isolates of Human Coronavirus 229E Bypass the Endosome for Cell Entry

TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Activation of influenza viruses by proteases from host cells and bacteria in the human airway epithelium

Novel insights into proteolytic cleavage of influenza virus hemagglutinin

Potentiation of infectivity and pathogenesis of influenza virus by host and bacterial proteases

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes

Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects

Teicoplanin potently blocks the cell entry of 2019-nCoV

The SWISS-MODEL Repository-new features and functionality

Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers

BacMam production and crystal structure of nonglycosylated apo human furin at 1.89Åresolution

Halogen Bonding at the Active Sites of Human Cathepsin L and MEK1 Kinase: Efficient Interactions in Different Environments

SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects

Membrane-Anchored Serine Proteases: Host Cell Factors in Proteolytic Activation of Viral Glycoproteins, Act. Viruses by Host Proteases

The biology and therapeutic targeting of the proprotein J o u r n a l P r e -p r o o f convertases

Processing of the Ebola virus glycoprotein by the proprotein convertase furin

Furin cleavage of the respiratory syncytial virus fusion protein is not a requirement for its transport to the surface of virus-infected cells

Implication of proprotein convertases in the processing and spread of severe acute respiratory syndrome coronavirus

Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics

A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues

TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of

Murine Models after Coronavirus Infection

Aprotinin and similar protease inhibitors as drugs against influenza

Protection of mice by a protease inhibitor, aprotinin, against lethal Sendai virus pneumonia

Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation

Alpha-1 antitrypsin inhibits SARS-CoV-2 infection

Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV2-Priming Protease TMPRSS2

Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide

Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients

A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses

A broad-spectrum virus-and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2

Cross-linking peptide and repurposed drugs inhibit of SARS-CoV-2

Teicoplanin for treating MRSA pneumonia

Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)

Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2

Incidence of coinfections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study

Superinfections in patients treated with Teicoplanin as anti-SARS-CoV-2 agent

HIV protease inhibitors: a review of molecular selectivity and toxicity

Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein

Mutations in the fusion peptide and heptad repeat regions of the Newcastle disease virus fusion protein block fusion

HIV-1 inhibition by a peptide

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

Characterization of a putative cellular receptor for HIV-1 transmembrane glycoprotein using synthetic peptides

A trimeric structural domain of the HIV-1 glycoprotein

Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor

Enfuvirtide (T-20): A Novel Human Immunodeficiency Virus Type 1 Fusion Inhibitor

Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2

Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides

Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors

Identification of a Novel Inhibitor J o u r n a l P r e -p r o o f against Middle East Respiratory Syndrome Coronavirus

Structure of the Fusion Core and Inhibition of Fusion by a Heptad Repeat Peptide Derived from the S Protein of Middle East Respiratory Syndrome Coronavirus

Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor

Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein

Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors

Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike

An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection

Cholesterol-conjugated peptide antivirals: a path to a rapid response to emerging viral diseases

A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity

Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity

Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets

Experimentally determined hydrophobicity scale for proteins at membrane interfaces

Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein

Alpha-1-antitrypsin interacts with gp41 to block HIV-1 entry into CD4+ T lymphocytes

Discovery and Optimization of a Natural HIV

Entry Inhibitor Targeting the gp41 Fusion Peptide

A Brief Review of Computer-Assisted Approaches to Rational Design of Peptide Vaccines

Therapeutics for COVID-19: from computation to practices-where we are, where we are heading to

Artificial Intelligence for COVID-19 Drug Discovery and Vaccine Development , Front

In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2

De novo design of protein peptides to block association of the SARS-CoV-2 spike protein with human ACE2

Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2

Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent

Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain

Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells

Dynamics of the ACE2-SARS-CoV-2mechanisms

Molecular Dynamics Simulations Related to SARS-CoV-2

Identification of Putative Cell-entry-inhibitory Peptides against SARS-CoV-2 from Edible Insects: An in silico Study

Antiviral Peptides as Promising Therapeutics against SARS-CoV-2

Identification of tuna protein-derived peptides as potent SARS-CoV-2 inhibitors via molecular docking and molecular dynamic simulation

In-silico design of a potential inhibitor of SARS-CoV-2 S protein

Structural basis of receptor recognition by SARS-CoV-2

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2, Science (80-. )

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Sergio Pantano at the Pasteur Institute of Montevideo

Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters

The SIRAH 2.0 Force Field: Altius, Fortius, Citius

Peptide therapeutics: current status and future directions

Novel delivery systems for improving the clinical use of peptides

Virological assessment of hospitalized patients with COVID-2019

Heuzé-Vourc'h, Designing inhaled protein therapeutics for topical lung delivery: what are the next steps?

Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications

The lungs as a portal of entry for systemic drug delivery

Inhaled protein/peptide-based therapies for respiratory disease

Mechanisms of macromolecule absorption by the lungs

Airway delivery of peptides and proteins using nanoparticles

Factors and strategies for improving buccal absorption of peptides

Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy

Resistance to enfuvirtide, the first HIV fusion inhibitor

Development of Peptide and Small-Molecule HIV-1 Fusion Inhibitors that Target gp41

Therapeutic peptides: Historical perspectives, current development trends, and future directions

Extrapulmonary manifestations of COVID-19

The trinity of COVID-19: immunity, inflammation and intervention

Peptides as drugs: is there a market?

Cleavage inhibition of the murine coronavirus spike protein by a furin-like enzyme affects cellcell but not virus-cell fusion

Comparative protein modelling by satisfaction of spatial restraints

The I-TASSER Suite: protein structure and function prediction

Protein structure prediction using Rosetta

De novo design of a fluorescence-activating β-barrel

A hierarchical approach to all-atom protein loop prediction

UCSF Chimera--a visualization system for exploratory research and analysis

The FoldX web server: an online force field

Dassault Syst mes BIOVIA, Discovery Studio Modeling Environment

CHARMM-GUI: a web-based graphical user interface for CHARMM

The HADDOCK2.2 Web Server: User-Friendly Integrative Modeling of Biomolecular Complexes

HPEPDOCK: a web server for blind peptideprotein docking based on a hierarchical algorithm

The ClusPro web server for protein-protein docking

ZDOCK: an initial-stage protein-docking algorithm

AVPdb: a database of experimentally validated antiviral peptides targeting medically important viruses

AVP-IC50 Pred: Multiple machine learning techniques-based prediction of peptide antiviral activity in terms of half maximal inhibitory concentration (IC50)

In silico approach for predicting toxicity of peptides and proteins

PRODIGY: a web server for predicting the binding affinity of protein-protein complexes

Scalable molecular dynamics with NAMD

The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling

GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers

VMD: Visual molecular dynamics

MDTraj: A Modern Open Library for the Analysis of Molecular Dynamics Trajectories